PDCD1 and neoplasm: The most successful outcome in this context is the development of INCB086550 (Compound 5, Figure 2) with a demonstrated reduction in tumor growth in humanized mice with CD34+ cells and elicited gene signatures associated with T cell activation, aligning with the blockade of the PD-L1/PD-1 pathway [46].